<DOC>
	<DOC>NCT01452607</DOC>
	<brief_summary>A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Pharmacokinetics of SPI-1005</brief_title>
	<detailed_description />
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Ebselen</mesh_term>
	<criteria>Healthy adult male and female subjects Within 15% of their ideal weights (Table of "Desirable Weights of Adults," Metropolitan Life Insurance Company, 1983) Medically healthy subjects with clinically insignificant screening results (laboratory profiles, medical histories, ECGs, physical exam); Voluntarily consented to participate in the study; Females of childbearing potential were either sexually inactive (abstinent) for 14 days prior to screening and throughout the study or used one of the following acceptable birth control methods: Intrauterine device (IUD) in place for at least 3 months prior to study; Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through study completion; Stable hormonal contraceptive for at least 3 months prior to study through completion of study; Surgical sterilization (vasectomy) of partner at least 6 months prior to study. Females of nonchildbearing potential were surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral oophorectomy at least 2 months prior to study). History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, otologic, or psychiatric disease; History or presence of alcoholism or drug abuse within the past 2 years; Hypersensitivity or idiosyncratic reaction to compounds related to ebselen; Use of any prescription medication within 14 days (with the exception of hormonal contraceptives) prior to or during the study; Use of any overthecounter medication including vitamins, herbal preparations, antacids, cough and cold remedies, etc., within 7 days prior or during the study; Use of any drugs or substances known to be strong inhibitors or inducers of cytochrome P450 enzymes within 28 days prior to dosing; Abnormal diet (for any reason) during the 30 days prior to dosing; Donation of whole blood within 56 days prior to the study; Plasma donation within 7 days prior to the study; Participation in another clinical trial within 30 days prior to the study; Female subjects who were pregnant or lactating; Hemoglobin &lt; 12.0 g/dL; Orthostatic vital signs which result in: A pulse increase of more than 30 beats per minute after 3 minutes standing (compared with semirecumbent pulse rate); or A pulse rate greater than 100 bpm after 3 minutes standing; or A drop in systolic blood pressure decrease of at least 20 mm Hg; or A diastolic blood pressure decrease of at least 10 mm Hg within 3 minutes of standing (compared with semirecumbent blood pressure).</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Ebselen</keyword>
</DOC>